Recent developments include the FDA granting Breakthrough Therapy Designation to TERN-701, and Merck's announcement to acquire Terns Pharmaceuticals for $6.7 billion, reflecting strategic interest in Terns' oncology pipeline.

• The FDA granted Breakthrough Therapy Designation to TERN-701 for treatment of adult patients with Ph+CML previously treated with two or more tyrosine kinase inhibitors, based on promising clinical trial data [S5].
• Merck announced a $6.7 billion acquisition of Terns Pharmaceuticals, agreeing to pay $53.00 per share, aiming to boost its oncology pipeline [N4][N8].
• Following the acquisition announcement, Terns Pharmaceuticals' stock price gained approximately 5% [N6].
• The acquisition deal and regulatory milestone have been covered extensively in recent Nasdaq.com articles highlighting the strategic value and market reaction [N1][N4][N6][N8].

The company’s lead candidate, TERN-701, has demonstrated promising clinical activity and safety in patients with chronic myeloid leukemia, supported by FDA Breakthrough Therapy Designation. The acquisition by Merck at a significant premium underscores the perceived strategic value of Terns’ pipeline and technology platform. The strong liquidity position provides financial flexibility to support ongoing development. The company’s experienced management and board with deep biopharma expertise support execution of clinical and regulatory strategies.

Terns Pharmaceuticals operates in a high-risk clinical-stage environment with no approved products and ongoing net losses. Regulatory risks include potential delays or denials in FDA approvals, compounded by government shutdowns and resource constraints. The company faces competition from established therapies and other emerging treatments in oncology. The acquisition by Merck introduces integration risks and potential changes in strategic priorities. Trade policy uncertainties and supply chain risks related to international operations may also impact development timelines and costs.

Terns Pharmaceuticals’ moat is primarily based on its novel therapeutic approach with TERN-701, which has received FDA Breakthrough Therapy Designation, indicating potential clinical differentiation in treating chronic myeloid leukemia. The company’s focus on allosteric inhibition of BCR::ABL1 and its clinical data supporting efficacy and tolerability provide a scientific and regulatory advantage. However, as a clinical-stage biopharma without commercial products, its moat depends on successful clinical development, regulatory approvals, and potential integration into Merck’s broader oncology portfolio.

• Regulatory Risks: Delays or failures in obtaining FDA approvals for product candidates, including potential impacts from FDA workforce reductions, government shutdowns, and regulatory reforms, could adversely affect development timelines and commercialization prospects [S2].
• Clinical Development Risks: As a clinical-stage company, Terns faces risks inherent in clinical trials, including potential failure to demonstrate safety and efficacy, which could impact the viability of its product candidates.
• Acquisition and Integration Risks: The announced acquisition by Merck may present integration challenges, changes in strategic focus, or disruptions that could affect ongoing development programs and operations.
• Financial Risks: The company has reported net losses and depends on external financing and partnerships to fund operations. Changes in capital markets or funding availability could impact its financial condition.
• Trade and Supply Chain Risks: Unfavorable government policies, tariffs, or geopolitical tensions, especially involving China, could increase costs or disrupt supply chains critical to product development and manufacturing [S2].

• Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for oncology indications.
• The company’s lead product candidate is TERN-701, an oral allosteric BCR::ABL1 inhibitor targeting chronic myeloid leukemia (Ph+CML) in the chronic phase without the T315I mutation.
• The FDA granted Breakthrough Therapy Designation (BTD) to TERN-701 for adult patients with Ph+CML previously treated with two or more tyrosine kinase inhibitors, based on data from the ongoing Phase 1/2 CARDINAL clinical trial showing promising activity and tolerability [S5].
• Terns Pharmaceuticals is incorporated in Delaware and headquartered in Foster City, California.
• The company is listed on the Nasdaq Global Select Market under the ticker TERN.
• As of December 31, 2025, Terns had cash and cash equivalents of approximately $525 million and short-term investments of approximately $494 million, totaling over $1 billion in current assets against current liabilities of about $16.4 million, resulting in a very strong current ratio of 62.41 and cash ratio of 62.09 [S1].
• For the fiscal year ended December 31, 2025, the company reported a net loss of approximately $96.2 million and basic and diluted EPS of -$1.03 [S1].
• The company’s board of directors and executive officers are detailed in the 10-K/A, with Amy Burroughs serving as CEO since February 2024 [S1].
• Terns Pharmaceuticals entered into an acquisition agreement with Merck valued at approximately $6.7 billion, with Merck agreeing to acquire Terns at $53.00 per share [N8].
• The acquisition is positioned to boost Merck’s oncology pipeline, reflecting the strategic value of Terns’ product candidates [N4].
• Following the acquisition announcement, Terns’ stock price gained approximately 5% [N6].
• The company’s clinical development strategy and regulatory interactions are publicly discussed, including the potential for strategic partnerships and commercialization arrangements [S5].
• The company is subject to risks related to FDA regulatory review delays, government shutdowns, and trade policy uncertainties as disclosed in SEC filings [S2].